about
Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myelomaNuclear export of proteins and drug resistance in cancerOncogenic activation of NF-kappaB.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.Multiple myeloma macrophages: pivotal players in the tumor microenvironment.Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.Expression of granulocyte colony stimulating factor receptor in human colorectal cancer.Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatmFocal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapyMacrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.Extracellular matrix in bone marrow can mediate drug resistance in myeloma.HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomideGenetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.The molecular characterization and clinical management of multiple myeloma in the post-genome era.Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells.Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip.Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myelomaCharacterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip.Effects of collagen iv on cisplatin-induced apoptosis of non-small cell lung cancer cells.The Different Mechanisms of Cancer Drug Resistance: A Brief Review.A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation.The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
P2860
Q27001749-CB500174-5B84-4428-A0D9-836F1606F4E9Q27012444-98657733-0E23-4617-86AA-22D2CEFCDA07Q33849388-842458E7-53ED-4891-82B2-8EF3F3E4FC82Q33889168-7DA7E82A-C2F0-4628-AB68-E02513938B6FQ34329152-339B60A7-B9AD-45C5-AA8E-550ECF4B780FQ34719436-CC7D707D-7DF8-4B93-A77F-B7D8FB49C5E6Q35521968-8B819F1E-8835-4910-BB60-FBA712FACAADQ35566338-0E7167F3-C5DA-4A97-8FCB-2F4693F7E75FQ36065096-51CF2AB9-176A-417B-A6AF-8B0A5B5F3B3FQ36092102-B1B8B5F4-8192-48FE-89E3-C1B14DCBA590Q36194659-45F200DF-C3CD-42D5-9F6D-12427F93FEA5Q36544516-07B4FD50-A9E9-4ABC-B5C5-23319C25F793Q36925154-8A23C8B9-C072-475C-B669-ABFC820BAA66Q36939043-4B864633-835C-4104-A8A0-7CDDDEDE6DA9Q37109468-762826F6-6AAA-4216-927F-789EABCD63B8Q38674749-BBE29529-35DB-4676-BFEB-0A34B69A347FQ38850981-D88D8AD9-1C90-4640-B5FB-82666ECBB920Q39109310-CFD53C3B-2251-4A92-8FE9-2129C78891BAQ39638460-FA9FF0E0-EDEB-413A-947A-B587336928CBQ39733964-A1E678FD-B0D6-4EDC-B6F3-9BA38A0E1A22Q40064019-D0E8E967-D850-4403-81E3-9C54E8F53326Q42658274-CDA93D4E-AF92-407A-8910-A96D1595AE99Q44020998-1E67E8E6-234D-4177-BCF2-03996F38F3A8Q44541080-0A41BF3F-A4A9-4F7B-B512-000575EA9CFAQ46972223-97205B21-11A7-407C-A0B6-62A8DD49F419
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The tumor microenvironment: focus on myeloma.
@ast
The tumor microenvironment: focus on myeloma.
@en
type
label
The tumor microenvironment: focus on myeloma.
@ast
The tumor microenvironment: focus on myeloma.
@en
prefLabel
The tumor microenvironment: focus on myeloma.
@ast
The tumor microenvironment: focus on myeloma.
@en
P1476
The tumor microenvironment: focus on myeloma.
@en
P2093
William S Dalton
P356
10.1016/S0305-7372(03)00077-X
P478
29 Suppl 1
P577
2003-05-01T00:00:00Z